Table 1.
Baseline characteristics of the study population
| Variables | 0VD (N = 988) |
DA (N = 302) |
1VD (N = 3295) |
2VD (N = 2114) |
3VD (N2190) |
P values |
|---|---|---|---|---|---|---|
| Age (years) | 62 {53, 72} | 66 {56, 74} | 63 {54, 71} | 67 {59, 75} | 71 {63, 78} | < 0.001 |
| Female gender | 585 (59.9) | 131 (44.0) | 966 (29.6) | 489 (23.3) | 587 (27.0) | < 0.001 |
| Hypertension | 368 (39.2) | 143 (49.7) | 1290 (41.6) | 875 (44.4) | 1088 (53.6) | < 0.001 |
| Hyperlipidemia | 427 (45.5) | 144 (49.5) | 1517 (48.9) | 1060 (53.6) | 1093 (53.9) | < 0.001 |
| Diabetes mellitus | 106 (11.0) | 51 (17.2) | 413 (12.9) | 342 (16.6) | 488 (23.0) | < 0.001 |
| IHD in the family | 347 (37.4) | 113 (40.1) | 1231 (40.5) | 765 (39.3) | 750 (37.9) | 0.3072 |
| Current smoker | 293 (32.4) | 100 (36.6) | 1303 (42.7) | 772 (39.4) | 654 (33.0) | < 0.001 |
| Overweighta | 463 (57.7) | 143 (55.6) | 1764 (67.3) | 1097 (66.7) | 1059 (64.4) | < 0.001 |
| Renal insufficiencyb | 107 (13.8) | 39 (15.4) | 353 (13.8) | 310 (19.0) | 457 (28.0) | < 0.001 |
| EF < 50% | 107 (22.1) | 37 (25.2) | 282 (19.5) | 258 (28.7) | 427 (42.3) | < 0.001 |
| Previous stroke | 36 (3.6) | 15 (5.0) | 113 (3.4) | 111 (5.3) | 189 (8.6) | < 0.001 |
| Treatment | ||||||
| Any revascularisationc | 26 (2.6) | 15 (5.0) | 2764 (83.9) | 1816 (85.9) | 1688 (77.1) | < 0.001 |
| PCI | 21 (2.1) | 11 (3.7) | 2728 (82.8) | 1588 (75.1) | 769 (35.1) | < 0.001 |
| CABG | 5 (0.5) | 4 (1.3) | 36 (1.1) | 228 (10.8) | 919 (42.0) | < 0.001 |
| Aspirin | 883 (90.9) | 288 (95.7) | 3177 (96.6) | 2039 (96.5) | 2048 (93.8) | <0.001 |
| P2Y12 receptor inhibitor | 668 (67.7) | 235 (78.1) | 3097 (94.2) | 1920 (90.9) | 1642 (75.2) | <0.001 |
| Beta blocker | 758 (78.1) | 263 (87.4) | 2964 (90.1) | 1892 (89.6) | 1975 (90.5) | <0.001 |
| ACE-inhibitor | 428 (44.1) | 147 (48.8) | 1641 (49.9) | 1175 (55.6) | 1363 (62.4) | <0.001 |
| Statin | 808 (83.2) | 277 (92.0) | 3103 (94.3) | 1968 (93.2) | 1978 (90.6) | <0.001 |
Parameters presented as numbers (percentages from non-missing data) or median (25th, 75th percentile)
Abbreviations: 0VD zero-vessel disease, DA diffuse atherosclerosis, 1VD one-vessel disease, 2VD two-vessel disease, 3VD three-vessel disease, IHD ischemic heart disease, EF ejection fraction, PCI percutaneous coronary intervention, CABG coronary by-pass graft operation, P2Y12-inhibitor P2Y12 receptor inhibitor, ACE angiotensin-converting-enzyme
aOverweight defined as body mass index ≥25
bRenal insufficiency defined as estimated glomerular filtration rate < 60 ml/min/1.73m2 using MDRD equation
cRevasculrisation defined as PCI within 30 days, and CABG within 60 days of non-ST-elevation myocardial infarction